Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25730232 | 0.84 | NOS3 (0.32) | NOS3NOS1NOS2L3MBTL1 | |
| SCHEMBL25526799 | 0.80 | PDE10A (0.34) | L3MBTL1 | |
| SCHEMBL27399729 | 0.80 | L3MBTL1 (0.37) | NOS3NOS1NOS2L3MBTL1IKBKB | |
| SCHEMBL23029845 | 0.80 | PDE10A (0.32) | L3MBTL1 | |
| SCHEMBL19781524 | 0.80 | L3MBTL1 (0.49) | L3MBTL1 | |
| SCHEMBL25730238 | 0.77 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL25730233 | 0.74 | — | — | |
| SCHEMBL23029802 | 0.71 | FYN (0.34) | — | |
| SCHEMBL11477117 | 0.71 | KDM4E (0.54) | L3MBTL1 | |
| SCHEMBL25149773 | 0.71 | ATM (0.41) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023144559-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | AdoRx Therapeutics Limited (GB) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | NOS3 3295/4885NOS1 2924/4885NOS2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.